0001104659-21-134772.txt : 20211105
0001104659-21-134772.hdr.sgml : 20211105
20211105084904
ACCESSION NUMBER: 0001104659-21-134772
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211102
FILED AS OF DATE: 20211105
DATE AS OF CHANGE: 20211105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PARMAR KUSH
CENTRAL INDEX KEY: 0001664281
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40969
FILM NUMBER: 211382467
MAIL ADDRESS:
STREET 1: C/O AUDENTES THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY ST., SUITE 2650
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entrada Therapeutics, Inc.
CENTRAL INDEX KEY: 0001689375
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813983399
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6 TIDE STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-305-1825
MAIL ADDRESS:
STREET 1: 6 TIDE STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: CycloPorters, Inc.
DATE OF NAME CHANGE: 20161104
4
1
tm2132054-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-11-02
0
0001689375
Entrada Therapeutics, Inc.
TRDA
0001664281
PARMAR KUSH
C/O ENTRADA THERAPEUTICS, INC.
6 TIDE STREET
BOSTON
MA
02210
1
0
1
0
Common Stock
2021-11-02
4
C
0
318616
A
649771
I
See Footnote
Common Stock
2021-11-02
4
C
0
2371739
A
3021510
I
See Footnote
Common Stock
2021-11-02
4
C
0
564217
A
564217
I
See Footnote
Common Stock
2021-11-02
4
C
0
254512
A
3276022
I
See Footnote
Common Stock
2021-11-02
4
C
0
318140
A
882357
I
See Footnote
Common Stock
2021-11-02
4
P
0
250000
20
A
1132357
I
See Footnote
Series Seed Preferred Stock
2021-11-02
4
C
0
318616
0
D
Common Stock
318616
0
I
See Footnote
Series A Preferred Stock
2021-11-02
4
C
0
2371739
0
D
Common Stock
2371739
0
I
See Footnote
Series A Preferred Stock
2021-11-02
4
C
0
564217
0
D
Common Stock
564217
0
I
See Footnote
Series B Preferred Stock
2021-11-02
4
C
0
254512
0
D
Common Stock
254512
0
I
See Footnote
Series B Preferred Stock
2021-11-02
4
C
0
318140
0
D
Common Stock
318140
0
I
See Footnote
Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
On November 2, 2021, Opportunities purchased 250,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.
/s/ Jared Cohen, as Attorney-in-Fact
2021-11-05